{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-051257","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2021-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.351388+00:00","generated_at":"2026-06-28T23:31:36.146694+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Helix Acquisition Corp. announces business combination with MoonLake Immunotherapeutics; $115M PIPE","bullets":["Helix (HLXA) to combine with MoonLake Immunotherapeutics AG, a Swiss immuno-dermatology biotech.","PIPE of $115M at $10.00/share from investors including sponsor affiliate and existing MoonLake holders.","Combined company to rename as MoonLake Immunotherapeutics; Helix Class B shares convert to Class A 1:1.","Closing expected late Q4 2021/early Q1 2022, subject to shareholder approvals and minimum $150M cash condition.","Post-closing board: 7 directors (4 designated by MoonLake, 2 by Helix, plus Jorge Santos da Silva)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-051257","json":"https://secwatch.observer/filing/0001213900-21-051257.json","markdown":"https://secwatch.observer/filing/0001213900-21-051257.md","text":"https://secwatch.observer/filing/0001213900-21-051257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/0001213900-21-051257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872-8k_helixacq.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:31:36.146694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}